| Management target | Revenue FY27 |
|---|
| Revenue growth | Q2 +28%, H1 +23% YoY |
|---|---|
| Margins | EBITDA margin 14.7% Q2 vs 11.0%; H1 13.7% vs 9.8% |
| Order book | Phase III pipeline 28 molecules vs 25 in Mar-26 |
| Demand visibility | Healthy order book; biotech funding up ~60% |
| Management confidence | Upgraded FY27 outlook; H2 seen stronger |
Growth
H1 revenue ₹4,887 Cr (+23%). Q2 CDMO +36%, CHG +32%, PCH +13%. H1 loss narrowed to ₹64 Cr from ₹181 Cr.
Outlook
FY27 revenue growth guided at 19-20% with meaningfully higher profitability. H2 expected stronger than H1. Lexington sterile fill-finish expansion on track.
Risks
Bayer distribution agreement expires Dec 2026 (₹475 Cr FY26 revenue, under 2% FY27 impact). Net debt rose to ₹4,859 Cr from ₹4,164 Cr.
Investor Presentation filed with NSE, NSE: PPLPHARMA. Summary written with AI assistance from the document.
Piramal Pharma Ltd: key numbers
- Share price
- ₹232.80
- Market cap
- ₹30,994 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -148.4×Sector 46.1×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Piramal Pharma Price Movement Clarification
Piramal Pharma clarified a news item regarding a $1.7 million (₹11.39 Cr) investment from the Government of Ontario, stating it does not require material disclosure.
- Value
- ₹11.39 Cr